| 16.39 0.12 (0.74%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.05 | 1-year : | 23.42 |
| Resists | First : | 17.17 | Second : | 20.05 |
| Pivot price | 16.25 |
|||
| Supports | First : | 15.79 | Second : | 14.93 |
| MAs | MA(5) : | 16.52 |
MA(20) : | 16.19 |
| MA(100) : | 15.14 |
MA(250) : | 12.51 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 61.7 |
D(3) : | 68.3 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 17.4 | Low : | 8.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VTRS ] has closed below upper band by 41.9%. Bollinger Bands are 18% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.6 - 16.7 | 16.7 - 16.8 |
| Low: | 15.98 - 16.1 | 16.1 - 16.21 |
| Close: | 16.21 - 16.38 | 16.38 - 16.55 |
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Thu, 09 Jul 2026
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Sun, 05 Jul 2026
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Sun, 05 Jul 2026
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Yahoo Finance
Wed, 01 Jul 2026
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky - The National Law Review
Tue, 23 Jun 2026
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,160 (M) |
| Shares Float | 1,160 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 48,020 (K) |
| Shares Short P.Month | 41,120 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.59 |
| Profit Margin | -2.1 % |
| Operating Margin | 6.7 % |
| Return on Assets (ttm) | 2.3 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 8.1 % |
| Gross Profit (p.s.) | 5 |
| Sales Per Share | 12.55 |
| EBITDA (p.s.) | 3.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,170 (M) |
| Levered Free Cash Flow | 2,240 (M) |
| PE Ratio | -54.64 |
| PEG Ratio | 0.1 |
| Price to Book value | 1.3 |
| Price to Sales | 1.3 |
| Price to Cash Flow | 8.76 |
| Dividend | 0.11 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|